TMCnet News
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - A 2017 Update - Research and MarketsThe "Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2017 Update" report has been added to Research and Markets' offering. Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 16 bln in 2016. Sales of anti-VEGF ophthalmic products continue to rise, while Avastin has come to an inflection point, also by the first approval of an Avastin biosimilar by the FDA. The forthcoming patent expires in the major markets have attracted a number of companies with global development of Avastin biosimilars in advanced clinical stages. So far, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term. The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies, proteins or vaccines for treatment of cancer and neo-angiogenic eye dseases. Competitor projects are listed in a tabular format providing information on:
Key Topics Covered: Oncology 1. Marketed Products in Oncology
2. Biosuperiors in Oncology
3. Biosimilars in Oncology
Ophthalmology 4. Marketed Products in Ophthalmology
5. Biosuperiors in Ophthalmology
6. Biosimilars in Ophthalmology
For more information about this report visit https://www.researchandmarkets.com/research/29d4ck/competitor View source version on businesswire.com: http://www.businesswire.com/news/home/20171117005679/en/ |